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To the Editor
As healthcare systems in many countries 
buckle under the immense pressure of rising 
COVID cases, a drug which can reduce emergency 
visits would be a huge boon. The results of the 
STOIC trial, therefore, are very uplifting [1]. In-
haled budesonide, a safe and simple intervention, 
seems to reduce hospital visits by almost 90% 
among mild COVID cases. None of the published, 
peer-reviewed trials have yet shown tangible 
benefits for this endpoint. In fact, seldom do 
therapeutic strategies show an effect size of this 
magnitude [2].
Therefore, it is only prudent to examine the 
data closely — is the effect of budesonide limited 
to reduction in emergency visits, or does it alter 
pathobiology of disease progression. Although 
the study excluded patients with recent use of 
inhaled or systemic glucocorticoids, there was 
a 15% prevalence of current or past asthma in 
both groups. Viral infections are known triggers 
of asthma, as acknowledged by the authors, 
which may present as worsening breathlessness 
leading to emergency visit. It is possible that it 
is only reversing the airway hyperreactivity in 
those already at risk, and not altering COVID 
pathophysiology. It would be interesting to know 
if the difference in outcomes is being dispropor-
tionately driven by this subset. 
Patients in the treatment arm showed faster 
improvement in systemic symptoms, and lower 
antipyretic requirement. However, the biological 
plausibility of this effect is unclear. Systemic ef-
fects of 800 μg of inhaled budesonide are minimal, 
and it would be unusual to expect reduction in 
systemic inflammation. Unfortunately, the study 
did not collect data on inflammatory markers 
to explore this aspect. Moreover, the difference 
in respiratory symptom scores is not signifi-
cant, while the difference in systemic symptom 
scores is. Also, the faster clinical recovery in the 
budesonide group plateaued after day-14, and 
the perceived difference in clinical recovery re-
mained the same until day-28. Possibly there may 
be a bias in self-reporting due to the non-place-
bo-controlled nature of the study. Above all, the 
decision to terminate the trial early despite such 
a small number of events (3 in the treatment group 
vs 11 in the control group) raises strong concerns 
of chance association.
The situation of a COVID physician is no 
better than that of Coleridge’s Mariner [3] — sur-
rounded by a sea of over 100,000 studies, 100 clin-
ical trials, and few dozen treatment options — yet 
only one or two drugs actually changing clinical 
outcomes [4]. In this situation, a 90% reduction 
in emergency visits is by itself an unparalleled 
feat. Such magnitude of effect is not seen with 
any other treatment, and the work of the authors 
is laudable. However, understanding exactly what 
drives this phenomenon is of utmost importance.
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